Status:
RECRUITING
Prescription of Valproate and Derivatives in Women of Childbearing Age: Qualitative Study
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Psychiatric Disorder
Eligibility:
FEMALE
16+ years
Brief Summary
The prescription of valproate in women of childbearing age has decreased by 82% in France, for mood disorders. Exposure to valproate during pregnancy 60%. However, the ANSM sent an alert document in A...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subject (≥16 years old)
- Female gender
- Prescription of Valproate and/or derivatives (Sodium Divalproate, Valpromide, Valproic Acid, Sodium Valproate) in an indication of psychiatric disorder for the period from January 1, 2021 to December 31, 2022,
- Subject not opposing, after information, the reuse of their data for the purposes of this research
- Holders of parental authority who do not object, after information, to the reuse of their child's data for the purposes of this research
- Exclusion criteria:
- Subject and/or holder of parental authority having expressed opposition to participating in the study
- Impossibility of providing the subject with informed information (difficulties in understanding the subject, etc.)
Exclusion
Key Trial Info
Start Date :
January 2 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 2 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06499779
Start Date
January 2 2024
End Date
May 2 2026
Last Update
July 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Psychiatrie 2 - CHU de Strasbourg - France
Strasbourg, France, 67091